Breast tumor xenografts: Diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody

Radiology

Volumn 248, Issue 3, 2008, Pages 844-851

  Kim, Hyunki ^a   Morgan, Desiree E ^a   Zeng, Huadong ^b,d   Grizzle, William E ^c   Warram, Jason M ^d   Stockard, Cecil R ^d   Wang, Deli ^d   Zinn, Kurt R ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; LUCIFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRA 8; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BREAST TUMOR; CANCER MODEL; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; MOUSE; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE MODELS, ANIMAL; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 51549089094     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2483071740     Document Type: Article

References (38)

1. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
2. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
3. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
4. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-1759.
5. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-567.
6. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-818.
7. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-113.
8. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J 1997;16:5386-5397.
9. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7:821-830.
10. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997;7:831-836.
11. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-820.
12. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-1170.
13. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-14367.
14. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-960.
15. Buchsbaum DJ, Zhou T, Grizzle WE, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003;9:3731-3741.
16. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-1077.
17. Liu GH, Wang SR, Wang B, Kong BH. Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer 2006;16:1777-1782.
18. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006;103:14901-14906.
19. Pusztai L, Hortobagyi GN. High-dose chemotherapy: how resistant is breast cancer? Drug Resist Updat 1998;1:62-72.
20. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999;1:113-117.
21. Woodhams R, Matsunaga K, Kan S, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005;4:35-42.
22. Woodhams R, Matsunaga K, Iwabuchi K, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005;29:644-649.
23. Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006;24:319-324.
24. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-2036.
25. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006;239:632-649.
26. Matsuki M, Inada Y, Nakai G, et al. Diffusion-weighed MR imaging of pancreatic carcinoma. Abdom Imaging 2007;32:481-483.
27. Ichikawa T, Erturk SM, Motosugi U, et al. High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR Am J Roentgenol 2007;188:409-414.
28. Rohrbacher DB. Statistical treatment for rejection of deviant values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Anal Chem 1991;63:139-146.
29. Sack I, Gedat E, Bernarding J, Buntkowsky G, Braun J. Magnetic resonance elastography and diffusion-weighted imaging of the sol/gel phase transition in agarose. J Magn Reson 2004;166:252-261.
30. Sternberg SR. Biomedical image processing. IEEE Comput 1983;16:22-34.
31. Jiang J. Linear and generalized linear mixed models and their applications. New York, NY: Springer, 2007.
32. Galecki AT. General class of covariance structures for two or more repeated factors in longitudinal data analysis. Commun Stat Theory Methods 1994;23:3105-3119.
33. Naik DN, Rao SS. Analysis of multivariate repeated measures data with a Kronecker product structured covariance matrix. J Appl Stat 2001;28:91-105.
34. Neter J, Kutner MH, Nachtsheim JC, Wasserman W. Applied linear statistical models. Columbus, Ohio: McGraw-Hill, 1996.
35. Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 2007;6:866-875.
36. Chou CP, Wu MT, Chang HT, et al. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol 2007;14:561-573.
37. Fan X, Medved M, Karczmar GS, et al. Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging 2007;25:593-603.
38. Momiyama N, Ishikawa T, Ichikawa Y, Shimada H, Katayama A, Ozawa Y. Early prediction of response to primary chemotherapy by sequential FDG-PET in patients with advanced breast cancer [in Japanese]. Nippon Rinsho 2007;65(suppl 6):385-388.